Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Liabilities and Shareholders Equity (2017 - 2026)

DiaMedica Therapeutics filings provide 10 years of Liabilities and Shareholders Equity readings, the most recent being $53.1 million for Q1 2026.

  • Quarterly Liabilities and Shareholders Equity rose 36.7% to $53.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $203.0 million through Mar 2026, up 4.36% year-over-year, with the annual reading at $61.4 million for FY2025, 32.42% up from the prior year.
  • Liabilities and Shareholders Equity hit $53.1 million in Q1 2026 for DiaMedica Therapeutics, down from $61.4 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $62.0 million in Q2 2023 and bottomed at $30.2 million in Q1 2023.
  • Average Liabilities and Shareholders Equity over 5 years is $47.3 million, with a median of $49.3 million recorded in 2024.
  • The largest annual shift saw Liabilities and Shareholders Equity skyrocketed 80.3% in 2022 before it plummeted 44.59% in 2025.
  • DiaMedica Therapeutics' Liabilities and Shareholders Equity stood at $34.4 million in 2022, then surged by 57.46% to $54.2 million in 2023, then decreased by 14.43% to $46.3 million in 2024, then soared by 32.42% to $61.4 million in 2025, then fell by 13.51% to $53.1 million in 2026.
  • Per Business Quant, the three most recent readings for DMAC's Liabilities and Shareholders Equity are $53.1 million (Q1 2026), $61.4 million (Q4 2025), and $57.0 million (Q3 2025).